<DOC>
	<DOCNO>NCT00856674</DOCNO>
	<brief_summary>The purpose study evaluate safety several dose level CCL2-LPM patient IgA Nephropathy high level protein urine .</brief_summary>
	<brief_title>Safety Study Intravenous CCL2-LPM Patients With IgA Nephropathy</brief_title>
	<detailed_description>In spite adequate blood pressure control diet , 30 percent patient IgA nephropathy continue secrete large amount protein urine high likelihood progress end-stage renal disease 5-10 year eventually require dialysis kidney transplant . In IgA nephropathy , injured kidney tissue secrete messenger recruit white blood cell ( leukocyte ) kidney . This messenger chemokine , CCL2 . As consequence CCL2 also excrete urine measure evidence inflammation kidney . This study evaluate safety new potential therapy , CCL2-LPM ( leukocyte population modulator ) , IgA nephropathy . CCL2-LPM compose messenger chemokine , CCL2 , fuse enzyme inhibits protein production leukocytes prevents leukocytes migrate kidney . The CCL2 end molecule target small subset leukocyte correspond receptor CCL2 surface . After CCL2 bind receptor drawn inside cell carry enzyme cell . The targeted cell prevent enter kidney cause damage . Thus , CCL2-LPM may interrupt ongoing cycle inflammation lead end-stage renal disease .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Proteinuria</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<criteria>Biopsy proven IgA nephropathy GFR &gt; 30 mL/min Urinary protein &gt; 700 mg/day Stable serum creatinine Urine CCL2/creatinine &gt; 250 pg/mg Stable dos medication ACEI and/or ARB maximize control hypertension proteinuria Other cause nephropathy Pregnant nursing female Prednisone &gt; 10 mg/day Other prohibit medication BP &gt; 140/90 BMI &gt; 35 Concurrent infection require treatment Clinical significant concurrent medical condition Known allergy sensitivity formulation ingredient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>IgA nephropathy</keyword>
	<keyword>chemokine fusion protein</keyword>
	<keyword>leukocyte population modulator</keyword>
	<keyword>phase-1</keyword>
</DOC>